105 related articles for article (PubMed ID: 24675576)
1. Hepatitis C virus replication compartment formation: mechanism and drug target.
Chukkapalli V; Randall G
Gastroenterology; 2014 May; 146(5):1164-7. PubMed ID: 24675576
[No Abstract] [Full Text] [Related]
2. Oxysterol-binding protein is a phosphatidylinositol 4-kinase effector required for HCV replication membrane integrity and cholesterol trafficking.
Wang H; Perry JW; Lauring AS; Neddermann P; De Francesco R; Tai AW
Gastroenterology; 2014 May; 146(5):1373-85.e1-11. PubMed ID: 24512803
[TBL] [Abstract][Full Text] [Related]
3. Inhibition of HCV replication by cyclophilin antagonists is linked to replication fitness and occurs by inhibition of membranous web formation.
Madan V; Paul D; Lohmann V; Bartenschlager R
Gastroenterology; 2014 May; 146(5):1361-72.e1-9. PubMed ID: 24486951
[TBL] [Abstract][Full Text] [Related]
4. The cyclophilin inhibitor SCY-635 disrupts hepatitis C virus NS5A-cyclophilin A complexes.
Hopkins S; Bobardt M; Chatterji U; Garcia-Rivera JA; Lim P; Gallay PA
Antimicrob Agents Chemother; 2012 Jul; 56(7):3888-97. PubMed ID: 22585215
[TBL] [Abstract][Full Text] [Related]
5. Cyclophilin inhibitors for the treatment of HCV infection.
Fischer G; Gallay P; Hopkins S
Curr Opin Investig Drugs; 2010 Aug; 11(8):911-8. PubMed ID: 20721833
[TBL] [Abstract][Full Text] [Related]
6. Characterization of the Anti-Hepatitis C Virus Activity of New Nonpeptidic Small-Molecule Cyclophilin Inhibitors with the Potential for Broad Anti-Flaviviridae Activity.
Nevers Q; Ruiz I; Ahnou N; Donati F; Brillet R; Softic L; Chazal M; Jouvenet N; Fourati S; Baudesson C; Bruscella P; Gelin M; Guichou JF; Pawlotsky JM; Ahmed-Belkacem A
Antimicrob Agents Chemother; 2018 Jul; 62(7):. PubMed ID: 29760125
[TBL] [Abstract][Full Text] [Related]
7. NS5A inhibitors impair NS5A-phosphatidylinositol 4-kinase IIIα complex formation and cause a decrease of phosphatidylinositol 4-phosphate and cholesterol levels in hepatitis C virus-associated membranes.
Reghellin V; Donnici L; Fenu S; Berno V; Calabrese V; Pagani M; Abrignani S; Peri F; De Francesco R; Neddermann P
Antimicrob Agents Chemother; 2014 Dec; 58(12):7128-40. PubMed ID: 25224012
[TBL] [Abstract][Full Text] [Related]
8. Continuous de novo generation of spatially segregated hepatitis C virus replication organelles revealed by pulse-chase imaging.
Wang H; Tai AW
J Hepatol; 2017 Jan; 66(1):55-66. PubMed ID: 27599826
[TBL] [Abstract][Full Text] [Related]
9. Metabolism of phosphatidylinositol 4-kinase IIIα-dependent PI4P Is subverted by HCV and is targeted by a 4-anilino quinazoline with antiviral activity.
Bianco A; Reghellin V; Donnici L; Fenu S; Alvarez R; Baruffa C; Peri F; Pagani M; Abrignani S; Neddermann P; De Francesco R
PLoS Pathog; 2012; 8(3):e1002576. PubMed ID: 22412376
[TBL] [Abstract][Full Text] [Related]
10. Combination of a hepatitis C virus NS3-NS4A protease inhibitor and alpha interferon synergistically inhibits viral RNA replication and facilitates viral RNA clearance in replicon cells.
Lin K; Kwong AD; Lin C
Antimicrob Agents Chemother; 2004 Dec; 48(12):4784-92. PubMed ID: 15561857
[TBL] [Abstract][Full Text] [Related]
11. Cyclophilin inhibitors reduce phosphorylation of RNA-dependent protein kinase to restore expression of IFN-stimulated genes in HCV-infected cells.
Daito T; Watashi K; Sluder A; Ohashi H; Nakajima S; Borroto-Esoda K; Fujita T; Wakita T
Gastroenterology; 2014 Aug; 147(2):463-72. PubMed ID: 24786893
[TBL] [Abstract][Full Text] [Related]
12. The science of direct-acting antiviral and host-targeted agent therapy.
Pawlotsky JM
Antivir Ther; 2012; 17(6 Pt B):1109-17. PubMed ID: 23188746
[TBL] [Abstract][Full Text] [Related]
13. Hepatitis C: An unsuspected drug target.
Murray CL; Rice CM
Nature; 2010 May; 465(7294):42-4. PubMed ID: 20445618
[No Abstract] [Full Text] [Related]
14. Hepatitis C virus exploits cyclophilin A to evade PKR.
Colpitts CC; Ridewood S; Schneiderman B; Warne J; Tabata K; Ng CF; Bartenschlager R; Selwood DL; Towers GJ
Elife; 2020 Jun; 9():. PubMed ID: 32539931
[TBL] [Abstract][Full Text] [Related]
15. Targeting the Achilles' heel of hepatitis C virus.
Lemon SM
Hepatology; 1997 Apr; 25(4):1035-7. PubMed ID: 9096617
[No Abstract] [Full Text] [Related]
16. Targets for inhibition of hepatitis C virus replication.
Littlejohn M; Locarnini S; Bartholomeusz A
Antivir Ther; 1998; 3(Suppl 3):83-91. PubMed ID: 10726058
[TBL] [Abstract][Full Text] [Related]
17. Treating hepatitis C: can you teach old dogs new tricks?
Rice CM; You S
Hepatology; 2005 Dec; 42(6):1455-8. PubMed ID: 16317665
[TBL] [Abstract][Full Text] [Related]
18. SCY-635, a novel nonimmunosuppressive analog of cyclosporine that exhibits potent inhibition of hepatitis C virus RNA replication in vitro.
Hopkins S; Scorneaux B; Huang Z; Murray MG; Wring S; Smitley C; Harris R; Erdmann F; Fischer G; Ribeill Y
Antimicrob Agents Chemother; 2010 Feb; 54(2):660-72. PubMed ID: 19933795
[TBL] [Abstract][Full Text] [Related]
19. ACH-806, an NS4A antagonist, inhibits hepatitis C virus replication by altering the composition of viral replication complexes.
Yang W; Sun Y; Hou X; Zhao Y; Fabrycki J; Chen D; Wang X; Agarwal A; Phadke A; Deshpande M; Huang M
Antimicrob Agents Chemother; 2013 Jul; 57(7):3168-77. PubMed ID: 23629709
[TBL] [Abstract][Full Text] [Related]
20. Blunting the Swiss army knife of hepatitis C virus: inhibitors of NS3/4A protease.
White PW; Llinas-Brunet M; Bös M
Prog Med Chem; 2006; 44():65-107. PubMed ID: 16697895
[No Abstract] [Full Text] [Related]
[Next] [New Search]
